3+ hour, 24+ min ago  (304+ words) Pharmaceutical companies that made MFN deals with the Trump administration will be exempt from the tariffs, along with other exemptions. After months of threats, President Trump issued major tariffs on pharmaceutical products. The tariffs will do into effect in 120 days…...

1+ week, 6+ day ago  (504+ words) In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than what patients in the United Kingdom pay, two biotech companies focused on next-generation T-cell…...

4+ mon, 18+ hour ago  (257+ words) The majority of respondents not already enrolled in the program have concerns that the program won't survive until the point when they need it. Anxiety surrounding Medicare is nothing new. However, recent political events have brought these worries into the…...

4+ mon, 3+ week ago  (460+ words) The booming obesity drug market is redefining prescriber influence, with nurse practitioners and physician associates emerging as key decision-makers that life sciences marketers can no longer afford to overlook. The obesity treatment market is expanding at an unprecedented pace. According…...

5+ mon, 2+ day ago  (298+ words) Nine drugs from leading manufacturers will participate in HRSA's new 340B rebate model pilot program, set to begin in 2026, which aims to evaluate a rebate-based framework for future drug pricing models amid ongoing industry litigation. The US Health Resources and Services…...

5+ mon, 3+ week ago  (353+ words) The company's CEO will reportedly joining the President to announce the deal. Another major pharmaceutical company is striking a deal with President Trump. AstraZeneca is set to announce a deal with the administration on Friday afternoon, according to a report…...

6+ mon, 2+ week ago  (1573+ words) With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma's formula for navigating the new age of innovation, where running from risk is not an option. In reality, of course, Hudson…...

7+ mon, 2+ week ago  (177+ words) Rob Abbott, CEO, ISPOR, explains how health economics and outcomes research is helping healthcare systems measure the true value of treatments, improve patient outcomes, and address rising drug costs globally. Pharmaceutical Executive: How is Health Economics and Outcomes Research (HEOR)…...